Stanford Cancer Institute
Genitourinary

Prostate

Castration-Resistant (CRPC)

1st Line Metastatic

PSA or Bone Progression

Soft Tissue Progression

Rising PSA before and after study:
PROS0100
Phase I Tolerability/Palatability of TallyTM Synthetic Meal Replacement in Prostate Cancer
PI: Stafford
Sponsor: Stanford

VAR0170
Phase Ib Caborzaminib (Xi 184) in Combo w/Atezolizumab in Locally Advanced or Metastatic Solid Tumors
Cohort 6
PI: Srinivas Exelixis

PROS0086
Phase III 177Lu-PSMA-R2 Radio-Ligand Tx in Progressive Metastatic Castration-Resistant Prostate Cancer
Pt: Jagers Advanced Accelerator Applications Inc.

PROS0094
Phase II I-131-1095 RT Combo w/ Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Pt: Jagers Pending

Rising PSA before and after study:
PROS0100
Phase I Tolerability/Palatability of TallyTM Synthetic Meal Replacement in Prostate Cancer
PI: Stafford
Sponsor: Stanford

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold